GlaxoSmithKline Top Executives

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

GlaxoSmithKline PLC employes about 99.4 K people. The company is managed by 44 executives with total tenure of roughly 241 years, averaging almost 5.0 years of service per executive having 2259.93 employees per reported executive. Assessment of GlaxoSmithKline PLC management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with GlaxoSmithKline PLC future performance. Please check Risk vs Return Analysis.

Search Insiders

 
Refresh
  Emma Walmsley  CEO
Chief Executive Officer, Executive Director
  Andrew Witty  CEO
CEO, Executive Director
  Brian McNamara  CEO
Chief Executive Officer - GSK Consumer Healthcare

  GlaxoSmithKline PLC Return on Sales

GlaxoSmithKline PLC Management Team Effectiveness

GlaxoSmithKline PLC has Return on Asset of 7.78 % which means that on every $100 spent on asset it made $7.78 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 50.81 %, implying that it generated $50.81 on every 100 dollars invested. GlaxoSmithKline PLC management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current Return on Investment is estimated to increase to 23.20. The current Return on Average Assets is estimated to increase to 0.07GlaxoSmithKline PLC Return on Average Assets are decreasing as compared to previous years. The last year's value of Return on Average Assets was reported at 0.07. The current Tangible Assets Book Value per Share is estimated to increase to 14.38, while Goodwill and Intangible Assets are estimated to decrease to under 32.9 B. The current Total Liabilities is estimated to decrease to about 57 B. The current Current Liabilities is estimated to decrease to about 22.5 BThe current Weighted Average Shares is estimated to increase to about 5.9 B. The current Weighted Average Shares Diluted is estimated to increase to about 5.5 B

GlaxoSmithKline PLC Workforce Comparison

GlaxoSmithKline PLC is rated # 4 in number of employees category among related companies. The total workforce of Drug Manufacturers?General industry is currently estimated at about 682,230. GlaxoSmithKline PLC retains roughly 99,437 in number of employees claiming about 15% of equities under Drug Manufacturers?General industry.

GlaxoSmithKline PLC Profit Margins

The company has Net Profit Margin of 15.29 %, which may imply that it executes well on its competitive polices and has a good control over its expenditures and variable costs. This is very large.

GlaxoSmithKline PLC Benchmark Summation

The output start index for this execution was eight with a total number of output elements of fifty-three. The Indexes of lowest and highest values over a specified period line shows minimum and maximum index of GlaxoSmithKline PLC price series. View also all equity analysis or get more info about indexes of lowest and highest values math operators indicator.

GlaxoSmithKline PLC Stakeholders

Emma Walmsley Chief Executive Officer, Executive Director
Andrew Witty CEO, Executive Director
Brian McNamara Chief Executive Officer - GSK Consumer Healthcare
Deborah Waterhouse Chief Executive Officer - ViiV Healthcare
Moncef Slaoui Chairman of Global Vaccines, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Luke Miels President - Global Pharmaceuticals
Hal Barron Chief Scientific Officer, President - Research & Development, Executive Director
Luc Debruyne President - Global Vaccines
Bill Louv Senior Vice President - Core Business Services
Roger Connor President - Global Manufacturing & Supply
Abbas Hussain President Global Pharmaceuticals
Phil Thomson Senior Vice President - Global Communications
Nick Hirons Senior Vice President - Global Ethics and Compliance
James Ford Senior Vice President General Counsel
Shah Hussain President - Europe, Japan & EMAP
Patrick Vallance President - Pharmaceuticals R&D
Regis Simard President - Pharmaceutical Supply Chain
Claire Thomas Senior Vice President - Human Resources
Daniel Troy Sr. VP and General Counsel
Vindi Banga Senior Independent Non-Executive Director
Lynn Elsenhans Independent Non-Executive Director
Daniel Podolsky Non-Executive Independent Director
Roy Anderson Non-Executive Independent Director
Philip Hampton Independent Non-Executive Director
Simon Dingemans CFO, Executive Director, Member of Corporate Admin. and Transactions Committee and Member of Fin. Committee
Vivienne Cox Non-Executive Independent Director
Judy Lewent Non-Executive Independent Director
Hans Wijers Independent Non-Executive Director
Stephanie Burns Non-Executive Independent Director
Urs Rohner Non-Executive Independent Director
Marvinder Banga Senior Non-Executive Independent Director
Deryck Maughan Senior Independent Non-Executive Director
Jesse Goodman Non-Executive Independent Director
Laurie Glimcher Non-Executive Independent Director
Manvinder Banga Non-Executive Director
Stacey Cartwright Non-Executive Independent Director
Iain Mackay Chief Financial Officer, Executive Director
Charles Bancroft Non-Executive Director
Diana Conrad Senior Vice President - Human Resources
Sally Jackson Senior Vice President - Global Communications and CEO Office
Victoria Whyte Company Secretary
David Redfern Chief Strategy Officer
Jonathan Symonds Independent Non-Executive Chairman of the Board
Karenann Terrell Chief Digital & Technology Officer

About GlaxoSmithKline PLC Management Performance

The success or failure of an entity such as GlaxoSmithKline PLC often depends on how effective the management is. GlaxoSmithKline PLC management team is responsible for propelling the future growth in the right direction and for administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of GlaxoSmithKline management before purchasing its stock. It's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the GlaxoSmithKline management is utilizing all available resources in the best possible way? Also, how well is the company doing, relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity. Please read more on our stock advisor page.
Last ReportedProjected for 2020
Return on Investment 18.28  23.20 
Return on Average Assets 0.07  0.07 
Return on Average Equity 0.61  0.90 
Return on Invested Capital 0.17  0.19 
Return on Sales 0.19  0.20 
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people.

GlaxoSmithKline PLC Manpower Efficiency

Return on GlaxoSmithKline PLC Manpower

Revenue Per Employee297.5 K
Revenue Per Executive909.3 M
Net Income Per Employee47.3 K
Net Income Per Executive55.9 M
Working Capital Per Employee31.9 K
Working Capital Per Executive72 M

Per Employee

GlaxoSmithKline PLC Per Employee Growth Over Time

  Net Income Per Employee

  Revenue Per Employee

Please check Risk vs Return Analysis. Please also try Financial Widgets module to easily integrated macroaxis content with over 30 different plug-and-play financial widgets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page